The estimated Net Worth of James M Mc Dermid is at least $403 Thousand dollars as of 30 June 2018. James Dermid owns over 1,179 units of Artivion Inc stock worth over $402,622 and over the last 8 years James sold CRY stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Dermid CRY stock SEC Form 4 insiders trading
James has made over 1 trades of the Artivion Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently James exercised 1,179 units of CRY stock worth $19,147 on 30 June 2018.
The largest trade James's ever made was exercising 1,179 units of Artivion Inc stock on 30 June 2018 worth over $19,147. On average, James trades about 168 units every 0 days since 2017. As of 30 June 2018 James still owns at least 22,518 units of Artivion Inc stock.
You can see the complete history of James Dermid stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Dermid's mailing address?
James's mailing address filed with the SEC is 1655, Roberts Boulevard Northwest, Kennesaw, Cobb County, Georgia, 30144, United States of America.
Insiders trading at Artivion Inc
Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman, and James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.
What does Artivion Inc do?
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
What does Artivion Inc's logo look like?
Complete history of James Dermid stock trades at Artivion Inc
Artivion Inc executives and stock owners
Artivion Inc executives and other stock owners filed with the SEC include:
-
James Mackin,
Chairman of the Board, President, Chief Executive Officer, Director -
D. Ashley Lee,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
Jean Holloway,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Michael Simpson,
Senior Vice President - Regulatory Affairs and Quality Assurance -
John Davis,
Senior Vice President - Global Sales and Marketing -
James Patrick Mackin,
Chairman, Pres & CEO -
Scott Capps,
Vice President - Clinical Research -
David Ashley Lee CPA, CPA,
Exec. VP, COO & CFO -
Jean F. Holloway Esq.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
John E. Davis,
Sr. VP of Global Sales & Marketing -
Harvey Morgan,
Independent Director -
Daniel Bevevino,
Independent Director -
Ronald McCall,
Presiding Independent Director -
Thomas Ackerman,
Independent Director -
Jon Salveson,
Independent Director -
James Bullock,
Independent Director -
Jeffrey Burbank,
Independent Director -
Marna Borgstrom,
Independent Director -
Greg Chodaczek,
IR Contact Officer -
Matthew Getz,
Vice President - Human Resources -
Dennis Maier,
Vice President - Operations -
Amy Horton,
Chief Accounting Officer, Vice President -
Thomas Bogenschutz,
Senior Vice President - EMEA, General Manager - Hechingen -
Dr. Marshall S. Stanton,
Sr. VP of Clinical Research & Chief Medical Officer -
Joshua Wells,
Sr. Director of Bus. Devel. -
Matthew A. Getz,
VP of HR -
Amy D. Horton CPA, CPA,
VP & Chief Accounting Officer -
Sherry M Saurini,
VP, Quality -
C Elkins Ronald,
Director -
James Benson,
Director -
James M Mc Dermid,
SVP, CHRO -
David C Gale,
VP-Research and Development -
William Robert Matthews,
Senior VP, Operations, Quality -
Thomas J Bogenschuetz,
VP, EMEA & General Manager -
Bruce G. Anderson,
VP, US Sales and Marketing -
Jeffrey W Burris,
Vice President & Gen. Counsel -
Gerald B Seery,
Sr. VP, Sales and Marketing -
John M Cook,
Director -
David P. Lang,
Sr. VP, Intl Sales & Marketing -
Steven G Anderson,
President, CEO and Chairman -
Thomas J Lynch,
VP - Reg. Aff./Quality Assur. -
Capital Management Oss,
10% owner -
Philip A Theodore,
VP, General Counsel -
Michaelstark Brian Jay Roth,
-
Sidney B Ashmore,
Vice President of Marketing -
Virginia C Lacy,
Director -
Dyne Bruce J Md Van,
Director -
Albert E Heacox,
Sr. VP-Laboratory Operations -
Vander James C Wyk,
VP - Product Integrity -
Kirby S Black,
Sr. Vice President, R&D -
David Fronk,
VP - Clinical Research -
Rochelle L. Maney,
VP, Quality -
Franz Peter Barthold,
VP, Research & Development -
Marshall S. Stanton,
SVP, Clinical & MD Affair -
Anthony B. Semedo,
Director